Zur Kurzanzeige

dc.contributor.authorKoehl, Niklas
dc.contributor.authorKuentz, Martin
dc.date.accessioned2021-05-10T07:48:57Z
dc.date.available2021-05-10T07:48:57Z
dc.date.issued2020-09-08
dc.identifier.doi10.1021/acs.molpharmaceut.0c00305
dc.identifier.urihttps://irf.fhnw.ch/handle/11654/32425
dc.description.abstractThe scientific rationale for selection of the surfactant type during oral formulation development requires an in-depth understanding of the interplay between surfactant characteristics and biopharmaceutical factors. Currently, however, there is a lack of comprehensive knowledge of how surfactant properties, such as hydrophilic-lipophilic balance (HLB), digestibility, and fatty acid (FA) chain length, translate into in vivo performance. In the present study, the relationship between surfactant properties, in vitro characteristics, and in vivo bioavailability was systematically evaluated. An in vitro lipolysis model was used to study the digestibility of a variety of nonionic surfactants. Eight surfactants and one surfactant mixture were selected for further analysis using the model poorly water-soluble drug nilotinib. In vitro lipolysis of all nilotinib formulations was performed, followed by an in vivo pharmacokinetic evaluation in rats. The in vitro lipolysis studies showed that medium-chain FA-based surfactants were more readily digested compared to long-chain surfactants. The in vivo study demonstrated that a Tween 20 formulation significantly enhanced the absolute bioavailability of nilotinib up to 5.2-fold relative to an aqueous suspension. In general, surfactants that were highly digestible in vitro tended to display higher bioavailability of nilotinib in vivo. The bioavailability may additionally be related to the FA chain length of digestible surfactants with an improved exposure in the case of medium-chain FA-based surfactants. There was no apparent relationship between the HLB value of surfactants and the in vivo bioavailability of nilotinib. The impact of this study's findings suggests that when designing surfactant-based formulations to enhance oral bioavailability of the poorly water-soluble drug nilotinib, highly digestible, medium chain-based surfactants are preferred. Additionally, for low-permeability drugs such as nilotinib, which is subject to efflux by intestinal P-glycoprotein, the biopharmaceutical effects of surfactants merit further consideration.en_US
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/32649208/en_US
dc.language.isoenen_US
dc.relation.ispartofMolecular Pharmaceuticsen_US
dc.accessRightsAnonymous*
dc.subjectdigestibilityen_US
dc.subjectlipolysisen_US
dc.subjectnilotiniben_US
dc.subjectpoorly water-soluble drugsen_US
dc.subjectsurfactantsen_US
dc.subjectsuspension.en_US
dc.titleExploring the Impact of Surfactant Type and Digestion: Highly Digestible Surfactants Improve Oral Bioavailability of Nilotiniben_US
dc.type01 - Zeitschriftenartikel, Journalartikel oder Magazin*
dc.volume17en_US
dc.issue9en_US
dc.audienceScienceen_US
fhnw.publicationStatePublisheden_US
fhnw.ReviewTypeAnonymous ex ante peer review of a complete publicationen_US
fhnw.InventedHereYesen_US
fhnw.PublishedSwitzerlandYesen_US
fhnw.pagination3202-3213en_US
fhnw.IsStudentsWorknoen_US
fhnw.publicationOnlineJaen_US


Dateien zu dieser Ressource

DateienGrösseFormatAnzeige

Zu diesem Eintrag gibt es keine Dateien.

Der Eintrag erscheint in:

Zur Kurzanzeige